In vivo, emodin and tetrahydropalmatine synergistically reduces colon cancer (HT-29) tumor size, increasing F4/80 expression, decreasing IL-6 and TGF-β levels, promoting tumor oxidation, and down-regulating p53 and STAT3 protein expression. Here, TP53 is linked to malignant colon neoplasm.